These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25730506)

  • 1. Adding rituximab to CODOX-M/IVAC chemotherapy in the treatment of HIV-associated Burkitt lymphoma is safe when used with concurrent combination antiretroviral therapy.
    Alwan F; He A; Montoto S; Kassam S; Mee M; Burns F; Edwards S; Wilson A; Tenant-Flowers M; Marcus R; Ardeshna KM; Bower M; Cwynarski K
    AIDS; 2015 May; 29(8):903-10. PubMed ID: 25730506
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensive chemotherapy with cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt lymphoma.
    Wang ES; Straus DJ; Teruya-Feldstein J; Qin J; Portlock C; Moskowitz C; Goy A; Hedrick E; Zelenetz AD; Noy A
    Cancer; 2003 Sep; 98(6):1196-205. PubMed ID: 12973843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. R-CODOX-M/R-IVAC versus DA-EPOCH-R in patients with newly diagnosed Burkitt lymphoma (HOVON/SAKK): final results of a multicentre, phase 3, open-label, randomised trial.
    Chamuleau MED; Stenner F; Chitu DA; Novak U; Minnema MC; Geerts P; Stevens WBC; Zenz T; van Imhoff GW; Wu KL; Demandt AMP; Kersten MJ; Terpstra WE; Tick LW; Deeren D; Van Den Neste E; Gregor M; Veelken H; Böhmer LH; Caspar CB; Mutsaers P; Refos JM; Sewsaran R; Fu L; Seefat RL; Uyl-de Groot CA; Dirnhofer S; Van Den Brand M; de Jong D; Nijland M; Lugtenburg P
    Lancet Haematol; 2023 Dec; 10(12):e966-e975. PubMed ID: 37922925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma.
    Noy A; Lee JY; Cesarman E; Ambinder R; Baiocchi R; Reid E; Ratner L; Wagner-Johnston N; Kaplan L;
    Blood; 2015 Jul; 126(2):160-6. PubMed ID: 25957391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modified cyclophosphamide, vincristine, doxorubicin, and methotrexate (CODOX-M)/ifosfamide, etoposide, and cytarabine (IVAC) therapy with or without rituximab in Japanese adult patients with Burkitt lymphoma (BL) and B cell lymphoma, unclassifiable, with features intermediate between diffuse large B cell lymphoma and BL.
    Maruyama D; Watanabe T; Maeshima AM; Nomoto J; Taniguchi H; Azuma T; Mori M; Munakata W; Kim SW; Kobayashi Y; Matsuno Y; Tobinai K
    Int J Hematol; 2010 Dec; 92(5):732-43. PubMed ID: 21120644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Excellent real-world outcomes of adults with Burkitt lymphoma treated with CODOX-M/IVAC plus or minus rituximab.
    Zhu KY; Song KW; Connors JM; Leitch H; Barnett MJ; Ramadan K; Slack GW; Abou Mourad Y; Forrest DL; Hogge DE; Nantel SH; Narayanan S; Nevill TJ; Power MM; Sanford DS; Sutherland HJ; Tucker T; Toze CL; Sehn LH; Broady R; Gerrie AS
    Br J Haematol; 2018 Jun; 181(6):782-790. PubMed ID: 29741758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in combination with CODOX-M/IVAC: a retrospective analysis of 23 cases of non-HIV related B-cell non-Hodgkin lymphoma with proliferation index >95%.
    Mohamedbhai SG; Sibson K; Marafioti T; Kayani I; Lowry L; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2011 Jan; 152(2):175-81. PubMed ID: 21092025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and 'unclassifiable' highly aggressive B-cell lymphoma.
    Corazzelli G; Frigeri F; Russo F; Frairia C; Arcamone M; Esposito G; De Chiara A; Morelli E; Capobianco G; Becchimanzi C; Volzone F; Saggese M; Marcacci G; De Filippi R; Vitolo U; Pinto A
    Br J Haematol; 2012 Jan; 156(2):234-44. PubMed ID: 22098541
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation.
    Sun H; Savage KJ; Karsan A; Slack GW; Gascoyne RD; Toze CL; Sehn LH; Abou Mourad Y; Barnett MJ; Broady RC; Connors JM; Forrest DL; Gerrie AS; Hogge DE; Narayanan S; Nevill TJ; Nantel SH; Power MM; Sutherland HJ; Villa D; Shepherd JD; Song KW
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15(6):341-8. PubMed ID: 25656914
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Favourable outcomes for high-risk diffuse large B-cell lymphoma (IPI 3-5) treated with front-line R-CODOX-M/R-IVAC chemotherapy: results of a phase 2 UK NCRI trial.
    McMillan AK; Phillips EH; Kirkwood AA; Barrans S; Burton C; Rule S; Patmore R; Pettengell R; Ardeshna KM; Lawrie A; Montoto S; Paneesha S; Clifton-Hadley L; Linch DC
    Ann Oncol; 2020 Sep; 31(9):1251-1259. PubMed ID: 32464282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study.
    Mead GM; Sydes MR; Walewski J; Grigg A; Hatton CS; Pescosta N; Guarnaccia C; Lewis MS; McKendrick J; Stenning SP; Wright D;
    Ann Oncol; 2002 Aug; 13(8):1264-74. PubMed ID: 12181251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The pharmacokinetics of high-dose methotrexate in people living with HIV on antiretroviral therapy.
    Dalla Pria A; Bendle M; Ramaswami R; Boffito M; Bower M
    Cancer Chemother Pharmacol; 2016 Mar; 77(3):653-7. PubMed ID: 26696583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens.
    Oosten LEM; Chamuleau MED; Thielen FW; de Wreede LC; Siemes C; Doorduijn JK; Smeekes OS; Kersten MJ; Hardi L; Baars JW; Demandt AMP; Stevens WBC; Nijland M; van Imhoff GW; Brouwer R; Uyl-de Groot CA; Kluin PM; de Jong D; Veelken H
    Ann Hematol; 2018 Feb; 97(2):255-266. PubMed ID: 29209924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified R-CODOX-M/IVAC chemotherapy regimens in Chinese patients with untreated sporadic Burkitt lymphoma.
    Chen M; Wang Z; Fang X; Yao Y; Ren Q; Chen Z; Tian Y; Pan F; Li X; Li Z; Cai Q; Huang H; Lin T
    Cancer Biol Med; 2021 Aug; 18(3):833-40. PubMed ID: 35979854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma.
    Evens AM; Carson KR; Kolesar J; Nabhan C; Helenowski I; Islam N; Jovanovic B; Barr PM; Caimi PF; Gregory SA; Gordon LI
    Ann Oncol; 2013 Dec; 24(12):3076-81. PubMed ID: 24146219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the addition of rituximab to CODOX-M/IVAC for Burkitt's lymphoma: a retrospective analysis.
    Barnes JA; Lacasce AS; Feng Y; Toomey CE; Neuberg D; Michaelson JS; Hochberg EP; Abramson JS
    Ann Oncol; 2011 Aug; 22(8):1859-64. PubMed ID: 21339382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Excellent immunological recovery following CODOX-M/IVAC, an effective intensive chemotherapy for HIV-associated Burkitt's lymphoma.
    Montoto S; Wilson J; Shaw K; Heath M; Wilson A; McNamara C; Orkin C; Nelson M; Johnson M; Bower M; Cwynarski K
    AIDS; 2010 Mar; 24(6):851-6. PubMed ID: 20124971
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chemotherapy regimen and rituximab in adult Burkitt lymphoma: a retrospective population-based study from the Nordic Lymphoma Group.
    Wästerlid T; Brown PN; Hagberg O; Hagberg H; Pedersen LM; D'Amore F; Jerkeman M
    Ann Oncol; 2013 Jul; 24(7):1879-1886. PubMed ID: 23446093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective study of Burkitt lymphoma treatment in adolescents and adults in Malawi.
    Painschab MS; Westmoreland KD; Kasonkanji E; Zuze T; Kaimila B; Waswa P; El-Mallawany NK; Tomoka T; Mulenga M; Montgomery ND; Fedoriw Y; Gopal S
    Blood Adv; 2019 Feb; 3(4):612-620. PubMed ID: 30796065
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A retrospective, multi-center analysis of treatment intensification for human immunodeficiency virus-positive patients with high-risk diffuse large B-cell lymphoma.
    Kassam S; Bower M; Lee SM; de Vos J; Fields P; Gandhi S; Nelson M; Montoto S; Tenant-Flowers M; Burns F; Marcus R; Edwards SG; Cwynarski K
    Leuk Lymphoma; 2013 Sep; 54(9):1921-7. PubMed ID: 23206228
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.